Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …

The hypomethylating agent azacitidine can prolong overall survival (OS) in patients with
higher risk-myelodysplastic syndromes (HR-MDS) compared to conventional regimens …

Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid
neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an …

国产阿扎胞苷治疗较高危骨髓增生异常综合征患者的疗效和安全性分析：多中心、前瞻性、单臂研究
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

Simple Summary Measurable residual disease (MRD) is emerging as an important
prognostic and predictive biomarker in acute myeloid leukemia (AML). However, its use is …

Higher-risk myelodysplastic syndromes (HR-MDS) are characterized by an increased risk of
acute myeloid leukemia (AML) transformation and compromised overall survival (OS)[1, 2] …

5-Azacitidine (5-AZA) is widely used for the treatment of higher-risk myelodysplastic
syndromes. However, response and survival rates vary considerably, while indicated …

To describe real-world treatment patterns and outcomes among adult patients with
myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA), patients …

The introduction of hypomethylating agents (HMAs) 5-azacytidine and decitabine has
altered the prognosis of patients with myelodysplastic syndrome (MDS). Over the past few …

Abstract Purpose of Review To understand how myelodysplastic syndromes (MDS)
transform to AML and to describe how transformation can be predicted and prevented …